thymine has been researched along with Carcinoma, Small Cell Lung in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scagliotti, G | 1 |
| Nishio, M | 1 |
| Satouchi, M | 1 |
| Valmadre, G | 1 |
| Niho, S | 1 |
| Galetta, D | 1 |
| Cortinovis, D | 1 |
| Benedetti, F | 1 |
| Yoshihara, E | 1 |
| Makris, L | 1 |
| Inoue, A | 1 |
| Kubota, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label, Randomized, Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin in Patients Requiring Second-Line Chemotherapy for Small Cell Lung Cancer That is Refractory or Sensitive to First-Line Platinum-Based Chemotherapy[NCT01904253] | Phase 2 | 18 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to The preliminary data does not suggest any safety signal, but an ad hoc interim analysis showed an imbalance of PFS between the two arms) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for thymine and Carcinoma, Small Cell Lung
| Article | Year |
|---|---|
A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Drug Combinations; Female; Humans; Male; Middle | 2016 |